KalVista appoints Jeb Ledell as COO; base salary $500k, 100k stock options

KalVista Pharmaceuticals, Inc.

Jebediah T. Ledell appointed COO effective December 16, 2024; brings 20+ years biotech ops experience.
Compensation: $500k base salary, 40% bonus target, inducement options for 100,000 shares vesting over 4 years.
Ledell previously COO at AVEO Oncology, Enzyvant Therapeutics, Compass Therapeutics, and Horizon Discovery Group.
Appointment supports KalVista's preparation for potential sebetralstat launch (HAE); PDUFA goal date June 17, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.